



Pre Amended A
7A
516-01

PATENT
Docket No. 290.00100101
(P-98086.00 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. KINCH) Group Art Unit: 1623
Serial No.: 09/640,935) Examiner: Unassigned
Filed: 17 August 2000)
For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER
(As Amended)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to taking up the above-identified patent application up for examination, please enter the following amendment:

In the Claims

Please amend the claims as follows:

1. (Amended) A pharmaceutical composition for treatment of a mammalian metastatic tumor including a population of cells which overexpress tyrosine kinase EphA2 having [a peptide] an amino acid sequence defining at least one extracellular epitope [of EphA2], said composition comprising a compound that specifically interacts with the extracellular epitope of EphA2 [in an amount effective] to reduce metastatic proliferation of said tumor, and a pharmaceutically acceptable carrier [therefor].

16. (Amended) A method of producing an antibody which inhibits the proliferation of metastatic tumor cells comprising

02/16/2001 YPOLITE1 00000003 09640935

01 FC:102
02 FC:103

880.00 OP
612.00 OP